1. Leukopaks (RUO, Mobilized, Clinical, and GMP Aligned)
Leukopaks remain one of the most common upstream inputs for immune cell workflows. We support formats that match how cell therapy teams actually operate.
RUO leukopaks
Fresh and cryopreserved options for discovery, preclinical, and process development.
Mobilized leukopaks
Mobilized options for programs requiring higher progenitor content or mobilized immune starting material.
Clinical and GMP aligned leukopakshttps://cgt.global/human-blood-products/mobilized-peripheral-blood/mobilized-peripheral-blood-leukopaks/
Fresh and cryopreserved clinical grade options designed for teams moving toward trials and manufacturing scale.
If you are treating leukopaks as a commodity purchase, you are accepting variability that shows up later as manufacturing surprises.
2. Isolated Immune and Stem Cells
Many teams do not want the overhead of in house isolation for every experiment.
CGT Global provides a broad catalog of isolated immune and stem cell products, including common lineages and subsets such as:
-
- PBMC's – PBMC's
-
T cells – T Cells (Lymphocytes)
-
Monocytes – Monocytes
-
B cells – B Cells (Lymphocytes)
-
NK cells – Natural Killer Cells
-
CD34+ stem and progenitor cells – CD34s (Hematopoietic Stem Cells)
-
Dendritic cells – Dendritic Cells
-
Macrophages – Macrophages
-
MSCs (Mesenchymal Stem Cells) – MSCs (Mesenchymal Stem Cells)
This is often the fastest path for teams that need ready to use cells and predictable performance without tying up internal bandwidth.
3. Bulk Cell Isolations Through CellsExpress
When you need scale and consistency, bulk isolations can be a better option than repeating internal isolations across multiple runs.
This supports teams who need:
-
Larger volumes of the same cell type
-
More consistent lots
-
Less internal processing workload
-
Faster iteration for process and assay work
4. Biospecimens Beyond Leukopaks
Not every workflow starts with leukopaks. CGT Global supports additional starting materials used across translational, immunology, and cell therapy programs, including:
5. Clinical Partner Access and GMP Support
The part most customers do not realize
CGT Global is building capability beyond supply. We are building infrastructure that supports programs as they transition from research into translational and clinical execution.
Through our clinical collaborations and GMP partner ecosystem, we help teams manage:
-
Collection coordination
-
Site level process consistency
-
Chain of custody aligned handling and logistics
-
Documentation expectations for clinical programs
-
Operational support for programs scaling toward trials
This is what prevents a program from getting stuck in the gap between “we can run the science” and “we can run it consistently.”
6. How Our Clinical Model Supports Autologous and Allogeneic Workflows
Autologous and allogeneic therapies have different constraints. Both fail for the same reason: the operational details are not controlled.
Autologous workflows
Autologous programs depend on patient specific collections and tight scheduling. One delay can turn into a missed manufacturing slot or a compromised timeline.
Our clinical access and coordination helps reduce risk by supporting:
-
predictable collection timing
-
clear handling expectations
-
logistics coordination that does not break the chain
-
consistent execution as programs scale
Allogeneic workflows
Allogeneic programs depend on repeatability, donor strategy, and scale. The cost of variability compounds quickly.
Our model supports:
-
consistent donor strategies
-
repeat donor access
-
standardized collection approaches
-
supply continuity and format selection that supports scale
7. What We Solve That Most Suppliers Do Not
This is the real reason customers consolidate with CGT Global.
Most suppliers can ship a leukopak. Most suppliers cannot support the real-world workflow needs behind cell therapy timelines.
What customers come to us for:
1. Consistency that reduces downstream variability
We focus on controlled collections, handling, and quality so your enrichment and expansion performance is not a constant guessing game.
2. Donor strategies, not one off donors
Programs that scale require repeatability. We support donor plans built around what your workflow needs, not random availability.
3. Fresh and cryopreserved formats built around your operations
Some teams need maximum biological performance. Others need scheduling control and repeatability. We support both without forcing you into a single model.
4. Clinical and GMP aligned support as you move toward trials
A lot of vendors disappear when your program gets serious. We build for that transition.
5. A team that actually responds when timelines shift
Cell therapy does not move in neat, predictable weekly cycles. When schedules change, your supplier either helps you recover or slows you down.
6. Fewer vendors, fewer points of failure
Many customers consolidate with us because it reduces vendor sprawl, documentation workload, and operational complexity.
If your program is juggling multiple suppliers for leukopaks, isolated cells, and downstream planning, that is an avoidable risk.
8. How to Choose the Right CGT Option for Your Workflow
Here is the quick mapping:
If you need ready to use cells fast
Use isolated immune and stem cells.
If you need flexible starting material for downstream work
Use RUO leukopaks.
If you need higher progenitor content
Use mobilized leukopaks.
If you need scale and consistency for one cell type, and you want to reduce internal processing workload, use bulk isolations.
Use bulk isolations.
If you are moving toward clinical requirements
Use clinical and GMP aligned products and support.
If you need help bridging collection, logistics, and execution
Use CGT Global’s clinical partner support model.
Bottom line
If you only use CGT Global for leukopaks, you are leaving capability on the table.
We support cell therapy teams across starting materials, isolated cells, bulk isolations, and clinical and GMP aligned execution so you can reduce variability and stop fighting operational bottlenecks.
